Loading clinical trials...
Loading clinical trials...
A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec
Conditions
Interventions
aglatimagene besadenovec + valacyclovir
External Beam Radiation Therapy (EBRT)
Locations
7
United States
Academic Urology and Urogynecology of Arizona
Peoria, Arizona, United States
Colorado Clinical Research
Lakewood, Colorado, United States
Urology Associates
Littleton, Colorado, United States
Chesapeake Urology Research Associates
Towson, Maryland, United States
Sheldon Freedman, MD Ltd.
Las Vegas, Nevada, United States
Summit Health
Saddle Brook, New Jersey, United States
Start Date
October 30, 2025
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2026
Last Updated
March 20, 2026
NCT06616597
NCT07115914
NCT07407608
NCT07391982
NCT07325721
NCT06862856
Lead Sponsor
Candel Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions